

LISTING OF CLAIMS:

Claim 1. (Original) A process for the production of α -interferon comprising the steps:

- i) inducing of human leukocytes by means of a virus,
- ii) treating the leukocytes with an enhancing agent selected from
 - a) xanthine, pyrimidinol and pyrimidinone, theophylline, theobromine, enprophylline, hypoxanthine, 8-phenyltheophylline, 2-amino-5-bromo-6-methylpyrimidinol, 2-amino-6-methyl-4-pyrimidinol and thymine;
 - b) an organic solvent selected from the group consisting of non-aromatic ketones, aliphatic or cyclic amides, alkylated aliphatic or cyclic urea derivatives and aliphatic or cyclic sulfoxides; or a combination of the compounds from a) with an organic solvent from b).

9
Claim 2. (Original) A process according to claim 1, characterized in that the leukocytes are monocytes.

17
Claim 3. (Previously Presented) A process according to claim 1, characterized in that the enhancing agent is added at the same time or up to 4 hours after the virus induction.

2
Claim 4. (Previously Presented) A process according to claim 1, characterized in that the virus is Sendai virus.

⁴
Claim ~~5~~. (Previously Presented) A process according to claim 1,
characterized in that the enhancing agent is theophylline.

⁵
Claim ~~6~~. (Withdrawn) A process according to claim 1, characterized in
that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

⁶
Claim ~~7~~. (Withdrawn) A process according to claim 1, characterized in
that the enhancing agent is thymine.

⁷
Claim ~~8~~. (Currently Amended) A process according to claim 1,
characterized in that the organic solvent is any of acetone, 2-butanone, 1,3-dimethyl-
2-imidazolidinone, dimethylsulfoxide, N-ethyl-2-pyrrolidinone, 4-methyl-2- pentanone,
N-methyl-2-pyrrolidinone, 2-pyrrolidinone, tetramethylene sulfoxide or and
N,N-dimethylacetamide.

⁸
Claim ~~9~~. (Original) A process according to claim ⁷~~8~~, characterized in that
the solvent is N-methyl-2-pyrrolidinone.

⁹
Claim 10. (Previously Presented) A process according to claim ~~2~~,
characterized in that the enhancing agent is added at the same time or up to 4 hours
after the virus induction.

¹²
Claim ~~11~~. (Previously Presented) A process according to claim ⁹~~2~~,
characterized in that the virus is Sendai virus.

¹⁸
Claim ~~12~~. (Previously Presented) A process according to claim ¹⁷~~3~~,
characterized in that the virus is Sendai virus.

¹¹
Claim ~~13~~. (Previously Presented) A process according to claim 10,
characterized in that the virus is Sendai virus.

¹³
Claim ~~14~~. (Previously Presented) A process according to claim ⁹~~2~~,
characterized in that the enhancing agent is theophylline.

¹⁹
Claim ~~15~~. (Previously Presented) A process according to claim ¹⁷~~3~~,
characterized in that the enhancing agent is theophylline.

³
Claim ~~16~~. (Previously Presented) A process according to claim ²~~4~~,
characterized in that the enhancing agent is theophylline.

¹⁴
Claim ~~17~~. (Withdrawn) A process according to claim ⁹~~2~~, characterized in
that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

²⁰
Claim ~~18~~. (Withdrawn) A process according to claim ¹⁷~~3~~, characterized in
that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

¹⁵
Claim 19. (Withdrawn) A process according to claim ⁹2, characterized in that the enhancing agent is thymine.

¹⁶
Claim 20. (Currently Amended) A process according to claim ⁹2, characterized in that the organic solvent is any of acetone, 2-butanone, 1,3-dimethyl-2-imidazolidinone, dimethylsulfoxide, N-ethyl-2-pyrrolidinone, 4-methyl-2-pentanone, N-methyl-2-pyrrolidinone, 2-pyrrolidinone, tetramethylene sulfoxide or and N,N-dimethylacetamide.